In the United States outcomes-based contracting (OBC) has long been proposed as a measure to reward innovation, based on actual performance of treatments and interventions in patient populations. However, the perceived and actual challenges in implementation have prevented many innovative contracts from leaving the drafting table. Recently, the potential use of artificial intelligence (AI) to predict suitable outcomes for patients to mitigate potential challenges has been discussed.

A: The greatest potential I see for AI is in clinical development. You can use AI to design trials in an intelligent way and this is where you start to see a potential cure for clinical trial inefficiencies. AI can scan clinical trial data in literature in real time and give you a landscape view of how your trials are performing and evolving, and it can alert you to challenges as the landscape shifts. You can predict the potential impact of design decisions before making them. For example, how should you sequence indications within clinical programs to maximize trial success?